NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD Caryn Mickelson, PharmD; Robin Moody, MPH; Eriko Onishi, MD; Bill Origer, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton; Trevor Douglass, DC, MPH; Jennifer Bowen

Audience: Robert Jaramillo, Reata Pharmaceuticals*; David Gross, Pfizer*; Rochelle Yang, Teva*; Erin Nowak, AbbVie*; Aileen Chin, Umpqua Health Pharmacy Student; Jennifer Davis, Gilead; Valerie Ng, LEO Pharma; Melissa Abbott, Eisai; Michele Sabados, Alkermes; Gary Parenteau, Dexcom; Paul Thompson, Alkermes; Amy Hale, Janssen; Teresa Blair, Ipsen; Matt Worthy, OHSU; Amy Breen, Teva; Laurie Krekemeyer, Reata Pharmaceutical; Tiina Andrews, UHA; Chris Ferrin, IHN; Brandie Feger, Advanced Health CCO; Suzanne Stewart, Supernus Pharmaceuticals; Mark Kantor, AllCare CCO; Mark Wolber, Sunovion; Saghi Maleki; Takeda Pharmaceuticals; Lori McDermott, Viking HCS; Haleh Ouranos, Ipsen Neuroscience; Deron Grothe, Braeburn; Ryan Taketomo; Washington State Health; Michael Foster, BMS; Chris Tanaka, ViVhealthcare; Sean Staff; Tim Chiu; Kailey Skelton, PacificSource CCO; Ted Raszka; Rob Booth, AbbVie; Mark Germann, LEO Pharma; Chris Johnson; Shelly Egbert; Carol Ricciotti, Aimmune; Danny Martinez, CSL Behring

(*) Provided verbal testimony
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:05 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Approval of Agenda and April 2023 Minutes presented by Roger Citron, RPh
   ACTION: Motion to approve, 2nd, all in favor
D. Department Update provided by Andrew Gibler, PharmD
E. Legislative Update provided by Trevor Douglass, DC

II. CONSENT AGENDA TOPICS

A. Quarterly Utilization Report
B. Oncology Prior Authorization (PA) Updates
   Recommendation:
   - Add: Omisirge® (omidubicel-onlv) and Zynyz™ (retifanlimab-dlwr) to Table 1 in the Oncology Agents prior authorization (PA) criteria
C. Orphan Drug Policy Updates
   Recommendation:
   - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Joenja® (leniolisib) and Lamzede® (velmanase alfa-tycv) based on FDA-approved labeling
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. ProDUR Report: Lan Starkweather, PharmD
B. RetroDUR Report: Dave Engen, PharmD
C. Oregon State Drug Review: Kathy Sentena, PharmD
   1. Hormone Replacement Therapy – A Focus on the Benefits and Risks of Estrogen
   2. Pharmacological Prevention and Treatment of Mpox
   3. Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Benefit for Children and Adolescents
D. Pharmacy & Therapeutics Operating Procedures: Sara Fletcher, PharmD
E. Evaluation of Evidence Methods
   1. Mental Health Clinical Advisory Group Methods: Andrew Gibler, PharmD
   2. Pharmacy & Therapeutics Committee Methods: Sarah Servid, PharmD

IV. DUR NEW BUSINESS
A. Low Dose Quetiapine Drug Use Evaluation:
   1. Mental Health Clinical Advisory Group Summary: Andrew Gibler, PharmD
   2. Drug Use Evaluation/Proposed PA Criteria: Sarah Servid, PharmD

Recommendations:
- Update PA criteria for low dose quetiapine to incorporate GAD
- Automatically approve PA requests for extended-release quetiapine with recent claims for an SSRI or SNRI
- Make quetiapine ER preferred

ACTION: Motion to approve, 2nd, all in favor

The Committee then recommended removing the auto PA for mental health specialists
ACTION: Motion to approve, 2nd, seven in-favor with two opposed

V. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Skyclarys™ (omaveloxolone) New Drug Evaluation: Deanna Moretz, PharmD

Recommendations:
- Maintain omaveloxolone as non-preferred on the PDL
- Implement proposed PA criteria to ensure medically appropriate use

ACTION: The Committee amended the proposed PA approval criteria to add questions to ensure the patient is ambulatory and able to swallow. They also amended the renewal criteria adding language regarding slowing progression.

Motion to approve, 2nd, all in favor

B. CGRP Inhibitors DERP Summary: Dave Engen, PharmD

Recommendations:
- No PDL changes recommended based on review of recently published evidence
- Update PA criteria as proposed
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

C. Severe Inflammatory Skin Disease PA Update: Deanna Moretz, PharmD

Recommendations:
- Revise “Targeted Immune Modulators for Severe Asthma and Atopic Dermatitis” and “Targeted Immune Modulators for Autoimmune Conditions” PA criteria to require a 4-week trial and failure (or contraindication) of either moderate to high potency topical steroids in combination with a topical calcineurin inhibitor (e.g., tacrolimus) or an oral immunomodulator (e.g., cyclosporine, methotrexate, or oral corticosteroids) before approval of dupilumab or upadacitinib treatment for atopic dermatitis.

ACTION: Motion to approve, 2nd, all in favor
D. Botulinum Toxins Class Update: Kathy Sentena, PharmD

Recommendations:
- No PDL changes recommended based on review of recently published evidence
- Update PA criteria to allow coverage under EPSDT
- Evaluate costs in executive session

ACTION: Motion to approve, 2nd, all in favor

E. Clostridioides difficile Drug Class Update & NDE: Deanna Moretz, PharmD

Recommendations:
- Maintain fidaxomicin as non-preferred on the PDL
- Retire current PA criteria and rely on “Non-Preferred” PA criteria to verify FDA-approved indication for C. difficile
- Designate fecal microbiota non-preferred on the PDL and implement proposed “Prevention of C. difficile Recurrence” PA criteria and include bezlotoxumab infusion and fecal microbiota enema
- Retire current bezlotoxumab PA criteria
- Evaluate costs in executive session

ACTION: The Committee rejected the proposal to retire the “Fidaxomicin” PA criteria
Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD Caryn Mickelson, PharmD; Robin Moody, MPH; Eriko Onishi, MD; Bill Origer, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Kathy Sentena, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. CGRP Inhibitors DERP Summary

Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

B. Botulinum Toxins Class Update

Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor
C. Clostridioides difficile Drug Class Update & NDE
   Make metronidazole capsules non-preferred
   ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN